DESIGN: Prospective, randomized, controlled study.
SETTING: Animal research laboratory.
SUBJECTS: Male, adult Sprague-Dawley rats.
INTERVENTIONS: MEASUREMENTS AND MAIN RESULTS: Survival was followed up for 24 hrs. Surviving rats were euthanized and inflammatory responses, and end organ
injuries were assessed. Both
glucosamine and
PUGNAc increased 24-hr survival compared with controls (control: 53%, GN: 85%,
PUGNAc: 86%, log-rank test, p < .05).
PUGNAc attenuated the
trauma-
hemorrhage-induced increase in serum
interleukin-6 (
sham surgery: 8 +/- 6, control: 181 +/- 36,
PUGNAc: 42 +/- 22 pg/mL, p < .05),
alanine transaminase (
sham surgery: 95 +/- 14, control: 297 +/- 56,
PUGNAc: 126 +/- 21 IU, p < .05),
aspartate transaminase (
sham surgery: 536 +/- 110, control: 1661 +/- 215,
PUGNAc: 897 +/- 155 IU, p < .05), and
lactate dehydrogenase (
sham surgery: 160 +/- 18, control: 1499 +/- 311,
PUGNAc: 357 +/- 99 IU, p < .05); however,
glucosamine had no effect on these serum parameters. Furthermore,
PUGNAc but not
glucosamine maintained O-GlcNAc levels in liver and lung and significantly attenuated the
NF-kappaB DNA activation in the liver. In the liver and heart, increased
inducible nitric oxide synthase expression was also attenuated in the
PUGNAc-treated group.
CONCLUSIONS: These results demonstrate that increasing O-GlcNAc with either
glucosamine or
PUGNAc improved 24-hr survival after
trauma-
hemorrhage. However, only
PUGNAc treatment attenuated significantly the subsequent tissue injury and inflammatory responses, suggesting that inhibition of O-GlcNAc removal may represent a new therapeutic approach for the treatment of
hypovolemic shock.